Chief Scientific Officer
Camil Sayegh, Ph.D is Chief Scientific Officer at Psivant. He brings 20 years of cross-sector experience in the biotech and pharmaceutical industry. Camil’s expertise spans pharmaceuticals, independent biotech companies and startups. At Psivant, Camil drives scientific innovation and strategic direction.
Before joining Psivant, Camil held several key roles including Chief Scientific Officer at Mitochondria Emotion, Inc. and Head of Complement Biology and Macrocycles at UCB, where he played a substantial role in the development and positioning of ZILBRYSQ® (zilucoplan). Previously, Camil was Senior Director and Head of Biology at Vertex Pharmaceuticals (Canada), where, under his leadership, the team discovered several groundbreaking compounds, including the FimH antagonist EB8018/TAK-018 for post-operative Crohn’s disease and the ApoL1 inhibitor for genetically defined FSGS. Camil began his career in 2024 at the Merck Frosst Centre for Therapeutic Research in Kirkland, Quebec.
Camil earned his Ph.D. in microbiology and immunology from McGill University in Montreal and completed the mini MBA program at the Desautels Faculty of Management at McGill University.